No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Amniotic epithelial cells |
- |
- |
- |
- |
1件: 26 |
2 |
Bortezomib |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
13件: 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
3 |
Ciclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
13件: 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
4 |
Costicosteroids |
- |
- |
- |
- |
1件: 26 |
5 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
6 |
Doxorubicin |
Doxorubicin |
D03899 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
5件: 26, 28, 34, 61, 331 |
7 |
Doxorubicin hydrochloride |
Doxorubicin |
D03899 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
4件: 26, 34, 61, 331 |
8 |
Etoposide |
Etoposide |
D00125, D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
9 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
10 |
Hu mik-beta-1 |
- |
- |
- |
- |
1件: 26 |
11 |
Human interferon beta |
Human interferon beta |
- |
- |
- |
2件: 13, 26 |
12 |
Interferon alfa |
Interferon alfa |
D03305 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
5件: 25, 26, 28, 56, 96 |
13 |
Interferon beta |
Human interferon beta |
- |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
14 |
Interferon beta-1a |
Human interferon beta |
- |
- |
- |
5件: 13, 14, 26, 96, 97 |
15 |
Kw-0761 |
- |
- |
- |
- |
1件: 26 |
16 |
Lamivudine |
Lamivudine |
D00353 |
- |
- |
6件: 26, 42, 46, 135, 265, 325 |
17 |
Lenalidomide |
Lenalidomide |
D04687 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
7件: 16, 26, 28, 34, 49, 284, 300 |
18 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
19 |
Mogamulizumab |
Mogamulizumab |
D09761 |
1件: CCR4 |
5件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Kaposi sarcoma-associated herpesvirus infection, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor |
1件: 26 |
20 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
21 |
Nk cells |
- |
- |
- |
- |
1件: 26 |
22 |
Pentosan polysulfate |
Pentosan polysulfate |
D05428 |
- |
- |
3件: 19, 26, 226 |
23 |
Pentoxifylline |
Pentoxifylline |
D00501 |
- |
- |
10件: 26, 56, 84, 93, 96, 113, 220, 222, 296, 298 |
24 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
25 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
26 |
Propantheline |
Propantheline |
D00481 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 26 |
27 |
Propantheline bromide |
Propantheline |
D00481 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 26 |
28 |
Raltegravir |
Raltegravir |
D06676 |
- |
- |
4件: 13, 26, 93, 265 |
29 |
Raltegravir and zidovudine |
Raltegravir |
D06676 |
- |
- |
1件: 26 |
30 |
Recombinant human interferon beta-1a |
Human interferon beta |
- |
- |
- |
1件: 26 |
31 |
Recombinant interferon alfa |
Interferon alfa |
D03305 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 26, 28 |
32 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
33 |
Tamibarotene |
Tamibarotene |
D01418 |
1件: RARA |
5件: Acute myeloid leukemia, Estrogen signaling pathway, Pathways in cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
2件: 26, 96 |
34 |
Valproic acid |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
10件: 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
35 |
Valproid acid plus corticosteroids |
- |
- |
- |
- |
1件: 26 |
36 |
Vincristine |
Vincristine |
D02197, D08679 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
4件: 26, 34, 61, 331 |
37 |
Vincristine sulfate |
Vincristine |
D02197, D08679 |
9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
3件: Gap junction, Pathogenic Escherichia coli infection, Phagosome |
3件: 26, 34, 61 |
38 |
Zidovudine |
Zidovudine |
D00413 |
- |
- |
6件: 25, 26, 135, 265, 325, 331 |
39 |
Zidovudine/lamivudine |
Lamivudine, Zidovudine |
D00353, D00413 |
- |
- |
1件: 26 |